Q1 Earnings Estimate for Immunovant Issued By Zacks Research

Immunovant, Inc. (NASDAQ:IMVT) – Stock analysts at Zacks Research cut their Q1 2026 earnings estimates for shares of Immunovant in a research note issued to investors on Tuesday, January 7th. Zacks Research analyst E. Bagri now expects that the company will earn ($0.82) per share for the quarter, down from their prior forecast of ($0.79). The consensus estimate for Immunovant’s current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Immunovant’s Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.38) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.90) EPS and FY2027 earnings at ($3.63) EPS.

Immunovant (NASDAQ:IMVT) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). During the same period in the previous year, the firm earned ($0.45) earnings per share.

IMVT has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $51.00 target price on shares of Immunovant in a research note on Friday, November 8th. Oppenheimer boosted their price objective on shares of Immunovant from $47.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Raymond James restated an “outperform” rating and issued a $36.00 price target on shares of Immunovant in a research note on Thursday, October 10th. Wells Fargo & Company reduced their target price on Immunovant from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Finally, Wolfe Research downgraded shares of Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.22.

Immunovant Stock Down 0.6 %

IMVT stock opened at $23.48 on Friday. The business’s fifty day simple moving average is $27.07 and its two-hundred day simple moving average is $28.58. Immunovant has a twelve month low of $23.08 and a twelve month high of $43.92. The firm has a market cap of $3.45 billion, a price-to-earnings ratio of -10.58 and a beta of 0.66.

Hedge Funds Weigh In On Immunovant

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMVT. FMR LLC grew its stake in Immunovant by 19.6% in the third quarter. FMR LLC now owns 12,537,571 shares of the company’s stock valued at $357,446,000 after acquiring an additional 2,053,688 shares during the period. Armistice Capital LLC raised its stake in shares of Immunovant by 57.0% during the 2nd quarter. Armistice Capital LLC now owns 3,396,909 shares of the company’s stock valued at $89,678,000 after purchasing an additional 1,232,909 shares during the period. Baker BROS. Advisors LP raised its position in shares of Immunovant by 163.7% in the third quarter. Baker BROS. Advisors LP now owns 1,225,410 shares of the company’s stock worth $34,936,000 after buying an additional 760,692 shares in the last quarter. Principal Financial Group Inc. increased its stake in Immunovant by 69.9% in the third quarter. Principal Financial Group Inc. now owns 951,124 shares of the company’s stock valued at $27,117,000 after acquiring an additional 391,436 shares during the last quarter. Finally, State Street Corp raised its position in Immunovant by 11.2% in the 3rd quarter. State Street Corp now owns 3,022,342 shares of the company’s stock worth $86,167,000 after purchasing an additional 303,386 shares during the period. 47.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Immunovant news, CEO Peter Salzmann sold 9,095 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $28.79, for a total transaction of $261,845.05. Following the completion of the sale, the chief executive officer now owns 994,789 shares of the company’s stock, valued at $28,639,975.31. This trade represents a 0.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Jay S. Stout sold 2,740 shares of the business’s stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $29.53, for a total transaction of $80,912.20. Following the completion of the sale, the chief technology officer now directly owns 142,186 shares of the company’s stock, valued at approximately $4,198,752.58. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 77,247 shares of company stock valued at $2,034,425. 5.90% of the stock is currently owned by insiders.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.